ATTO NASDAQ
Attovia Therapeutics, Inc.
1W: -5.8%
1M: +26.2%
3M: +786.8%
YTD: +4.1%
1Y: +327.6%
3Y: +122.3%
5Y: -37.3%
$22.79
+0.26 (+1.15%)
Weekly Expected Move ±12.8%
$17
$20
$23
$26
$29
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Watch
25
Insider+$52.4M
Congress—
ETF Holdings—
Key Statistics
Market Cap$980.7M
52W Range16.15-28
Volume175,769
Avg Volume435,279
Beta0.00
Dividend—
Analyst Ratings
No analyst coverage
Company Info
1091 Industrial Rd, Ste 310
San Carlos, CA 94070
US
San Carlos, CA 94070
US
About Attovia Therapeutics, Inc.
A clinical-stage biopharmaceutical company developing biotherapeutics for immune-mediated diseases using its ATTOBODY biologics platform. The company's lead candidate, ATTO-1310, targets interleukin-31 (IL-31), known as the 'itch cytokine,' for the treatment of chronic pruritic diseases including atopic dermatitis. Its pipeline also includes multi-specific candidates for other inflammatory diseases.
Latest News
Attovia Therapeutics, Inc.’s (NASDAQ:ATTO) Quiet Period To End on September 14th
Analysts Offer Insights on NA Companies: Fastenal Company (FAST) and Attovia Therapeutics, Inc. (ATTO) - theglobeandmail.com
Attovia Therapeutics to Participate in Upcoming Citi and Morgan Stanley Investor Conferences - Quiver Quantitative
Attovia Therapeutics to Participate in Upcoming Investor Conferences
Two investor events are on Attovia’s September calendar - stocktitan.net
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| WALSH COLIN | C-Conversion | 1,957,134 | — | 2026-08-06 |
| WALSH COLIN | C-Conversion | 478,498 | — | 2026-08-06 |
| WALSH COLIN | P-Purchase | 500,000 | $17.00 | 2026-08-06 |
| WALSH COLIN | C-Conversion | 18,181,830 | — | 2026-08-06 |
| WALSH COLIN | C-Conversion | 4,445,275 | — | 2026-08-06 |